Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gilead Sciences is conducting a study titled ‘A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer.’ The study aims to evaluate the safety, tolerability, and efficacy of sacituzumab govitecan-hziy (SG) in treating advanced triple-negative breast cancer (TNBC), focusing on objective response rate and progression-free survival.
The intervention being tested is sacituzumab govitecan-hziy, administered intravenously. This drug is designed to treat TNBC by potentially offering a new dosing schedule that could improve patient outcomes.
The study is interventional, non-randomized, and follows a sequential model without masking. Its primary purpose is treatment, with two phases assessing safety and efficacy.
The study began on April 30, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing recruitment.
This study could significantly impact Gilead Sciences’ stock performance by potentially introducing a new treatment option in the competitive oncology market. Positive results may enhance investor confidence and position Gilead favorably against competitors in the TNBC treatment space.
The study is ongoing, and further details are available on the ClinicalTrials portal.